BioVaxys Technology (BioVaxys Technology) Change In Inventory : $0.00 Mil (TTM As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Change In Inventory?

BioVaxys Technology's change in inventory for the quarter that ended in Jul. 2023 was $0.00 Mil. It means BioVaxys Technology's inventory stayed the same from Apr. 2023 to Jul. 2023 .

BioVaxys Technology's change in inventory for the fiscal year that ended in Oct. 2022 was $0.00 Mil. It means BioVaxys Technology's inventory stayed the same from Oct. 2021 to Oct. 2022 .

BioVaxys Technology's Total Inventories for the quarter that ended in Jul. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology Change In Inventory Historical Data

The historical data trend for BioVaxys Technology's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Change In Inventory Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Change In Inventory

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jul. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

BioVaxys Technology (OTCPK:BVAXF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioVaxys Technology's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioVaxys Technology's Inventory Turnover for the quarter that ended in Jul. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology's Inventory to Revenue for the quarter that ended in Jul. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

BioVaxys Technology Change In Inventory Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.